



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, April 10, 2025 1:00 p.m.– 5:00 p.m.
Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. **The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:**

ANALGESICS

1. Orally Disintegrating/Oral Spray Schedule II opioids
2. Short Acting Schedule II opioids
3. Short Acting Schedule III-IV opioids/Analgesic Combinations
4. NSAIDs

ANTICONVULSANTS

1. Second Generation

ANTI-INFECTIVES – SYSTEMIC

1. Macrolides and ketolides
2. Quinolones
3. Tetracycline Derivatives
4. Antiviral (Hepatitis C Agents)
5. Antiviral (Influenza)

BEHAVIORAL HEALTH

1. Injectable Antipsychotics (Injectable Long Acting)
2. Atypical Antipsychotics Oral, Transdermal

CARDIOVASCULAR

1. Ace Inhibitors
2. Ace Inhibitors/ Calcium Channel Blocker combinations
3. Angiotensin II Receptor / Neprilysin Blocker Combinations
4. Anti-Arrhythmics
5. Beta Blockers
6. Non-Dihydropyridine Calcium Channel Blockers
7. Antianginal & Anti-Ischemic

CENTRAL NERVOUS SYSTEM

1. Antimigraine Agents
6. Antimigraine Agents (CGRP Blocker/Modulators Preventative)
7. Antiparkinson and Restless Leg Syndrome
8. Multiple Sclerosis (Oral)
9. Amyotrophic Lateral Sclerosis (ALS) Agents

ENDOCRINOLOGY

1. Growth Hormone
2. Intermediate Acting Insulin
3. Premixed Rapid Combination Insulin
4. GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes

GASTROINTESTINAL

1. Antiemetic-Antivertigo Agents
2. Bile Acid Salts
3. Genitourinary/Renal Electrolyte Depleters (Kidney Disease)
4. Genitourinary/Renal Urinary Antispasmodics

GOUT

1. Gout

HEMATOLOGICS

1. Anticoagulants (Oral)

OPHTHALMIC

1. Allergic Conjunctivitis Agents
2. Antibiotics-Steroid Combinations
3. Alpha 2 Adrenergic Agents
4. Beta Blocker Agents/Combinations
5. Carbonic Anhydrase Inhibitors/Combinations
6. RHO Kinase Modifiers/Combinations

OTIC

1. Antibiotics
2. Anti-Infectives and Anesthetics
3. Anti-Inflammatory

RESPIRATORY

1. Beta-Adrenergic Handheld, Long Acting
2. Beta-Adrenergic, Nebulizers
3. Beta-Adrenergic, Oral
4. Orally Inhaled Anticholinergic/COPD Agents
5. Intranasal Rhinitis Agents
6. Leukotriene Modifiers
7. Low Sedating Antihistamine Combinations
8. First Generation Antihistamines

TOPICALS

1. Acne Agents
2. Antibiotics
3. Antiparasitics
4. Antiviral
5. Psoriasis
6. Rosacea Agents
7. Steroids (Low Potency)
8. Steroids (Very High Potency)

MISCELLANEOUS

1. Immunomodulators (Atopic Dermatitis)
2. Epinephrine, Self-Administered
3. Estrogen Agents (Vaginal Preparations)
4. Cytokine and Cam Antagonists
5. Hereditary Angioedema (HAE) Prophylaxis Agents

DIABETIC CONTINUOUS GLUCOSE MONITOR SUPPLIES

1. Diabetic Continuous Glucose monitor supplies

Diabetic Supplies

1. Diabetic Supplies

- V. Closing comments and adjournment